MPTP Model

Description

The MPTP model of Parkinson’s Disease is among the most widely used in the indication. Pathologically, it presents with dopaminergic neuron loss in the substantia nigra with associated depletion of striatal neuron terminals/dopamine levels. Additionally, the model may present with some behavioral deficits. Rotarod trials are employed to evaluate motor dysfunction; diseased animals demonstrate reduced latencies to fall from the rod.

  • Advantages: well-published, platform for testing symptomatic and neuroprotective drugs.
  • Disadvantages: does not fully replicate motor deficits observed in Parkinson’s Disease.
Model Systems
  • C57Bl/6 Mice
Standard Readouts
  • Percent weight change
  • Latency to fall (Rotarod)
Additional Readouts
  • Terminal histopathology and/or IHC analyses
  • Behavioral analyses
  • Custom assays
Representative DataClick Image to Enlarge
Mean Latency to Fall in the MPTP Model of Parkinson’s Disease

Animals are evaluated for motor dysfunction via rotarod assessment.

Assessment of Dopaminergic Neuron Loss in the MPTP Model of Parkinson’s Disease

Samples are assessed for dopaminergic neuron loss by tyrosine hydroxylase staining of the substantia nigra.

Daniel Lichtman

Managing Partner